Infographic | April 16, 2020

Use Of Preferred Providers Among Biologic Outsourcers

Source: ISR Reports

In Q42019, ISR surveyed outsourcers of biologic API and outsourcers of biologic drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing. The data show the majority of respondents use preferred providers for both large molecule API (59%) and large molecule drug product manufacturing (61%). To learn more, follow the links to the Biologic API and the Biologic Drug Product report previews.

VIEW THE INFOGRAPHIC!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: